Watchlist · 75/100Aug 7, 3:45 AM EDT
Denali Projects $10M-$12M Q3 AVLAYAH Sales as Launch Gains Traction
DNLI
Denali Therapeutics (DNLI) announced expectations of $10 million to $12 million in net product revenue from AVLAYAH for Q3, reflecting strong launch momentum. The company also highlighted progress in advancing two Alzheimer's disease programs into clinical dev…
- ▹AVLAYAH launch momentum with Q3 revenue guidance of $10M-$12M indicates early commercial traction.
- ▹Platform technology (transport vehicle) enables multiple CNS programs, including two Alzheimer's programs in clinic, supporting a strong moat.
Watchlist · 65/100Aug 7, 2:55 AM EDT
AVITA Medical Guides 2026 Revenue to $86M-$89M, Aims for Q4 Cash Flow Break-Even
AVHHLRCEL
AVITA Medical (RCEL) reported Q2 2026 revenue of $21.7 million, up 18% year-over-year and 13% sequentially, driven by its acute wound care portfolio. Management guided full-year 2026 revenue to $86M-$89M and targets cash flow break-even by Q4 2026, signaling c…
- ▹Strong revenue growth and clear path to cash flow break-even in Q4 2026, indicating commercial traction.
- ▹Single-asset focus with no recent regulatory catalysts; watch for pipeline expansion and profitability milestones.
Neutral · 62/100Aug 6, 10:55 PM EDT
Cytokinetics Aims for Majority Share in MyQorzo Market by 2026, Prepares nHCM Filing
CYTK
Cytokinetics (CYTK) reported strong Q2 2026 commercial execution for its heart drug MYQORZO, with a goal to capture over 50% of new-to-brand prescriptions by the end of 2026. The company also plans to submit a supplemental New Drug Application (sNDA) for obstr…
- ▹Strong commercial momentum for MYQORZO with >50% new-to-brand share target and European launch, but single-asset risk and no major regulatory catalyst beyond sNDA.
- ▹sNDA for nHCM in Q4 provides regulatory upside, but no platform or diversified pipeline to boost technology score.
Neutral · 55/100Aug 7, 1:25 AM EDT
Xenon Eyes AZK NDA Filing This Quarter, Cash Runway Through 2029
XENE
Xenon Pharmaceuticals (XENE) is on track to submit its New Drug Application (NDA) for AZK to the FDA later this quarter, following a successful pre-NDA meeting. The company also expects its current funding to support operations into 2029, providing a clear run…
- ▹Pre-NDA meeting success and imminent submission for azekalant (AZK) support regulatory progress, but no accelerated path or surrogate endpoint mentioned.
- ▹Single-asset focus with no platform or recent BD/M&A limits technology score; funding into 2029 reduces near-term dilution risk.
Neutral · 53/100Aug 7, 8:05 AM EDT
INmune Bio Guides Ebstrocel UK Submission to Late 2026, Details Cash Runway
INMB
INmune Bio (INMB) announced plans to submit the Marketing Authorization Application (MAA) for Ebstrocel to the UK's MHRA by the end of Q3 or early Q4 2026, following regulatory alignment and manufacturing progress. The company also outlined a monthly cash burn…
- ▹MHRA alignment and pediatric plan approval are positive regulatory steps, but no FDA involvement yet.
- ▹Single-asset clinical-stage company with high cash burn and no near-term revenue.
Neutral · 52/100Aug 7, 8:05 AM EDT
Arcturus Sets Q4 2026 Pivotal Readout for CF Therapy, Reclaims Full Rights to KOSTAIVE
ARCT
Arcturus Therapeutics (ARCT) announced it will make a Phase III decision for ARCT-032 in cystic fibrosis by Q4 2026, a key catalyst for its rare disease pipeline. The company also regained global rights to its COVID vaccine KOSTAIVE, potentially unlocking new…
- ▹Phase III decision for ARCT-032 in CF expected Q4 2026, but no accelerated path or regulatory clarity yet.
- ▹Regained global rights to KOSTAIVE, but single-asset focus and no near-term revenue cap commercial upside.
Neutral · 52/100Aug 7, 4:45 AM EDT
Corvus Sets 2027 Catalysts: PTCL Futility Readout and Atopic Dermatitis Data
CRVS
Corvus Pharmaceuticals (CRVS) provided updated timelines for its lead asset soquelitinib, a first-in-class selective ITK inhibitor. The company expects a futility analysis in peripheral T-cell lymphoma (PTCL) in Q1 2027 and topline data in atopic dermatitis (A…
- ▹First-in-class ITK inhibitor with multiple indications, but single-asset risk and no regulatory catalysts until 2027.
- ▹Phase 3 PTCL trial with futility analysis in Q1 2027 and AD topline in Q3 2027; no recent FDA interactions mentioned.
High Risk · 47/100Aug 6, 10:45 PM EDT
CytomX Sets Varseta-M Pivotal Trial for H1 2027, Extends Cash Runway to H2 2028
CTMX
CytomX Therapeutics announced that its lead asset, Varseta-M, an EpCAM-targeting ADC, is on track to enter a registrational study in metastatic colorectal cancer in the first half of 2027. The company also projects its cash runway to extend into the second hal…
- ▹Single-asset ADC with registrational start in H1 2027, but no accelerated path or regulatory clarity yet.
- ▹Cash runway into H2 2028 provides some buffer, but early-stage and single-asset risk cap upside.
High Risk · 45/100Aug 7, 1:46 AM EDT
Lineage Cell Therapeutics Extends Cash Runway to 2028, Eyes Key COR1 Data by Year-End
LCTX
Lineage Cell Therapeutics (LCTX) reported Q2 2026 results, extending its cash runway into Q3 2028. The company is targeting in vivo proof-of-concept data for its COR1 cell therapy candidate by year-end, a key catalyst for investors. Management highlighted prog…
- ▹Single-asset focus with early-stage pipeline, limited regulatory clarity.
- ▹Cash runway into Q3 2028 reduces near-term dilution risk, but no near-term catalysts.
High Risk · 42/100Aug 7, 2:15 AM EDT
Organogenesis Projects 2026 Revenue of $179M-$215M, Restructuring to Save $18M Annually
ORGO
Organogenesis Holdings (ORGO) provided 2026 revenue guidance of $179M-$215M, reflecting a challenging skin substitute market impacted by CMS actions. The company announced a restructuring in June expected to generate $18M in annual savings, which could support…
- ▹CMS actions causing market contraction and slow recovery, impacting revenue outlook.
- ▹Restructuring expected to cut $18M annually, but single-asset focus and market headwinds cap upside.